Iron and erythropoietin to heal and recover after intensive care (ITHRIVE): A pilot randomised clinical trial.

"Conflict of interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: EL is a Critical Care and Resuscitation Editor. David Griffith received fees for speaking from Fresenius Kabi (2021) and for BD advisory board participation (2020). In both bases, fees were paid directly to DGs group at the University of Edinburgh. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

"Funding This research was funded by competitive grants from the Intensive Care Foundation of Australia and New Zealand (2105) and the Future Health Research Fund WA Department of Health (2022/000278). Edward Litton is supported by a National Health and Medical Research Council Emerging Leadership Grant (GNT2017081)."

"This investigator-initiated, parallel-group, placebo-controlled, randomised feasibility trial was approved by the South Metropolitan Health Service Human Research Ethics Committee (ref: RGS0000004354). Trial registration occurred prospectively (ACTRN 12621000595819), and it was conducted according to the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement: extension to randomised pilot and feasibility trials (checklist provided, supplementary appendix). Prior to study enrolment, prospective, written informed consent was obtained from the participant or from the legal surrogate for participants who lacked capacity. Prospectively, no between-group analyses of clinical outcomes were planned in order to include pilot participants in the pivotal trial."